Tango Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello, everyone, and welcome. I'm Charles Zhu, I'm one of the Senior Biotech Analysts here at Guggenheim Securities. Our next fireside chat will be with the Tango Therapeutics, a clinical stage oncology biotech and synthetic lethality company. With us here today is CEO, Barbara Weber; as well as CSO, Alan Huang.
Barbara and Alan, thank you so very much for joining us here today. Before we go into Q&A, could you perhaps kick us off with a three-minute overview of your company platform and pipeline?
I think that the idea of Tango Therapeutics really came from my background in synthetic lethality and thinking about cancer genetics. The idea of Tango really is that it's a precision oncology company that we have used to build a CRISPR-based platform to discover novel synthetic lethal targets -- to discover novel synthetic lethal targets against specific tumor suppressor gene loss.
So at Tango, we've now built that platform and are building a drug discovery
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
